Non-steroidal Anti-inflammatory Drugs Market Growth, Size, Trends Analysis - By Disease Indication, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Non-steroidal Anti-inflammatory Drugs Market Introduction and Overview

According to SPER market research, 'Global Non-steroidal Anti-inflammatory Drugs Market Size- By Disease Indication, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Non-steroidal Anti-inflammatory Drugs Market is predicted to reach 40.44 billion by 2034 with a CAGR of 5.92%.

Nonsteroidal anti-inflammatory medications are often used to treat pain, inflammation, and fever. They are commonly used to relieve arthritis, muscle aches, headaches, menstrual cramps, and minor injuries such as sprains and strains. NSAIDs inhibit the formation of substances called prostaglandins in the body, which are responsible for pain and inflammation. These drugs, such as ibuprofen (Advil, Motrin) and naproxen (Aleve), are frequently available in over-the-counter and prescription strength formulations.

Restraints: The broad use of NSAIDs is limited by the possibility of major side effects such as cardiovascular events, gastrointestinal issues, renal failure, and hypersensitivity responses. Despite the relatively low individual risk for each patient, the cumulative usage of NSAIDs throughout populations increases the overall risk of adverse effects. This needs a rigorous review of individual patient risk factors before to prescribing NSAIDs, limiting the growth of the anti-inflammatory medications industry.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Disease Indication, By Route of Administration, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Pfizer Inc, Bayer AG, GSK plc, Dr. Reddys Laboratories Ltd, Viatris Inc, Teva Pharmaceutical Industries Ltd, Johnson and Johnson Services, Merck & Co, Inc. and others.

Non-steroidal Anti-inflammatory Drugs Market Segmentation:

By Disease Indication: Based on the Disease Indication, Global Non-steroidal Anti-inflammatory Drugs Market is segmented as; Arthritis, Migraine, Ophthalmic Diseases, Others.

By Route of Administration: Based on the Route of Administration, Global Non-steroidal Anti-inflammatory Drugs Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2548

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Non-steroidal Anti-inflammatory Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Non-steroidal Anti-inflammatory Drugs Market

7. Global Non-steroidal Anti-inflammatory Drugs Market, By Disease Indication (USD Million) 2021-2034

7.1. Arthritis
7.2. Migraine
7.3. Ophthalmic Diseases
7.4. Others

8. Global Non-steroidal Anti-inflammatory Drugs Market, By Route of Administration (USD Million) 2021-2034

8.1. Oral
8.2. Topical
8.3. Others

9. Global Non-steroidal Anti-inflammatory Drugs Market, By Distribution Channel (USD Million) 2021-2034

9.1. Hospital Pharmacy
9.2. Retail Pharmacy
9.3. Online Pharmacy

10. Global Non-steroidal Anti-inflammatory Drugs Market, (USD Million) 2021-2034

10.1. Global Hospital Pharmacy
10.2. Retail Pharmacy
10.3. Online Pharmacy Market Size and Market Share

11. Global Non-steroidal Anti-inflammatory Drugs Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Pfizer Inc
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Bayer AG
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. GSK plc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Dr. Reddys Laboratories Ltd
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Viatris Inc
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Teva Pharmaceutical Industries Ltd
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Johnson and Johnson Services, Inc
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Merck & Co., Inc
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Others